miRNA Quantification: Ultrafast Single-Molecule Fluorescence Assay

The relentless pursuit of faster, more accurate disease detection and personalized medicine is driving a revolution in molecular diagnostics. What began with PCR-based methods for identifying pathogens like HIV and Hepatitis C in the early 90s (Piatak et al., 1993; Yoshioka et al., 1992) has evolved into a sophisticated landscape of liquid biopsies and single-molecule analysis, promising to reshape healthcare as we know it. The recent surge in research, evidenced by publications spanning COVID-19 diagnostics (Wang et al., 2020) to advanced cancer detection (Ma et al., 2024; Cescon et al., 2020), isn’t merely incremental; it’s an exponential leap fueled by technological advancements.

For decades, diagnostics relied on amplifying genetic material – a process prone to inaccuracies and limitations. The initial breakthroughs with PCR for tuberculosis (Pao et al., 1990) and the subsequent development of rapid tests like Xpert MTB/RIF (Theron et al., 2014; World Health Organization, 2013) were game-changers, but still faced challenges with sensitivity and the detection of drug resistance. The emergence of multidrug-resistant strains of tuberculosis (Dheda et al., 2024) and Gram-negative bacteria (Macesic et al., 2025) underscores the urgent need for more precise and rapid diagnostic tools. The current wave of innovation addresses these limitations by moving towards amplification-free methods and single-molecule detection.

The core of this advancement lies in technologies like kinetic fingerprinting (Hayward et al., 2018; Johnson-Buck et al., 2015; Shin et al., 2020; Shin et al., 2023) and advanced microscopy techniques like DNA-PAINT (Jungmann et al., 2014). These methods allow researchers to identify and quantify individual molecules of DNA and RNA, providing a level of detail previously unattainable. Liquid biopsies, analyzing circulating tumor DNA (ctDNA) and other biomarkers in blood, are becoming increasingly sophisticated (Deveson et al., 2021; McDonald et al., 2019; Forshew et al., 2012). MicroRNAs (miRNAs), small non-coding RNA molecules involved in gene regulation, are also emerging as promising diagnostic and prognostic biomarkers (Nakamura et al., 2022; Xiong et al., 2017; Jang et al., 2021; Chandradoss et al., 2014; Pasquinelli et al., 2000; Roush & Slack, 2008; Johnson et al., 2005; Büssing et al., 2008; Boyerinas et al., 2010; Zhang et al., 2021; O’Brien et al., 2018; Condrat et al., 2020). The ability to accurately quantify these molecules, even in complex biological samples, is crucial for early disease detection and personalized treatment strategies.

The Forward Look: While the technology is impressive, several hurdles remain. Standardization and validation of these assays are critical for widespread clinical adoption. The analytical validity of ctDNA sequencing, as highlighted by Deveson et al. (2021), needs continuous refinement. Furthermore, the cost of these advanced techniques remains a barrier. However, the trajectory is clear. We’re on the cusp of a future where routine blood tests can provide a comprehensive molecular profile of an individual’s health, enabling earlier diagnosis, more targeted therapies, and ultimately, improved patient outcomes. Expect to see increased investment in automated platforms and machine learning algorithms (White et al., 2020; Ma et al., 2019) to streamline data analysis and reduce costs. The next five years will be pivotal in translating these scientific breakthroughs into tangible benefits for patients. The focus will shift from simply *detecting* disease to predicting its course and tailoring treatment accordingly – a truly personalized approach to medicine.